Financhill
Sell
16

IGMS Quote, Financials, Valuation and Earnings

Last price:
$1.13
Seasonality move :
-6.5%
Day range:
$1.10 - $1.16
52-week range:
$1.10 - $22.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
25.52x
P/B ratio:
1.40x
Volume:
149.1K
Avg. volume:
189.4K
1-year change:
-87.29%
Market cap:
$67.5M
Revenue:
$2.7M
EPS (TTM):
-$3.24

Analysts' Opinion

  • Consensus Rating
    IGM Biosciences has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 6 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $2.13, IGM Biosciences has an estimated upside of 88.05% from its current price of $1.13.
  • Price Target Downside
    According to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $1.13.

Fair Value

  • According to the consensus of 7 analysts, IGM Biosciences has 88.05% upside to fair value with a price target of $2.13 per share.

IGMS vs. S&P 500

  • Over the past 5 trading days, IGM Biosciences has overperformed the S&P 500 by 0.23% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • IGM Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • IGM Biosciences revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter IGM Biosciences reported revenues of $412K.

Earnings Growth

  • IGM Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter IGM Biosciences reported earnings per share of -$0.61.
Enterprise value:
-116.2M
EV / Invested capital:
--
Price / LTM sales:
25.52x
EV / EBIT:
--
EV / Revenue:
-43.39x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.73x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-57.38%
Net Income Margin (TTM):
-7308.51%
Return On Equity:
-159.45%
Return On Invested Capital:
-159.45%
Operating Margin:
-9461.17%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue -- $2.1M $2.7M $651K $412K
Gross Profit -- -- -- -- --
Operating Income -$228M -$263.5M -$208.6M -$65.1M -$39M
EBITDA -$221.9M -$255.2M -$199.5M -$62.9M -$36.6M
Diluted EPS -$5.37 -$4.78 -$3.24 -$0.98 -$0.61
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $373.3M $240.7M $438.4M $347.6M $193.6M
Total Assets $408.6M $298.1M $513.5M $423.4M $265.7M
Current Liabilities $17.2M $27.8M $44.7M $42.5M $37.6M
Total Liabilities $26.8M $53.2M $226.2M $220.2M $217.5M
Total Equity $381.8M $244.9M $287.3M $203.2M $48.2M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations -$5.9M -$192.2M -$153M -$48M -$34.8M
Cash From Investing -$225.6M $68.4M $64.2M -$14.7M $18M
Cash From Financing $219.4M $115.1M $2.4M $402K $420K
Free Cash Flow -$16.1M -$204.6M -$158.8M -$49.5M -$35.7M
IGMS
Sector
Market Cap
$67.5M
$33.6M
Price % of 52-Week High
5.02%
40.87%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-87.29%
-46.67%
Beta (5-Year)
0.579
0.744
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $1.20
200-day SMA
Sell
Level $8.19
Bollinger Bands (100)
Sell
Level 0.66 - 8.66
Chaikin Money Flow
Sell
Level -9.3M
20-day SMA
Sell
Level $1.24
Relative Strength Index (RSI14)
Sell
Level 35.16
ADX Line
Sell
Level 40.76
Williams %R
Buy
Level -85.3659
50-day SMA
Sell
Level $1.37
MACD (12, 26)
Sell
Level -0.13
25-day Aroon Oscillator
Sell
Level -64
On Balance Volume
Neutral
Level 27.9M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-6.2293)
Sell
CA Score (Annual)
Level (-3.8125)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.3539)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Stock Forecast FAQ

In the current month, IGMS has received 0 Buy ratings 6 Hold ratings, and 1 Sell ratings. The IGMS average analyst price target in the past 3 months is $2.13.

  • Where Will IGM Biosciences Stock Be In 1 Year?

    According to analysts, the consensus estimate is that IGM Biosciences share price will rise to $2.13 per share over the next 12 months.

  • What Do Analysts Say About IGM Biosciences?

    Analysts are divided on their view about IGM Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that IGM Biosciences is a Buy and believe this share price will drop from its current level to $3.00.

  • What Is IGM Biosciences's Price Target?

    The price target for IGM Biosciences over the next 1-year time period is forecast to be $2.13 according to 7 Wall Street analysts, 0 of them rate the stock a Buy, 1 rates the stock a Sell, and 6 analysts rate the stock a Hold.

  • Is IGMS A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for IGM Biosciences is a Hold. 6 of 7 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of IGMS?

    You can purchase shares of IGM Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IGM Biosciences shares.

  • What Is The IGM Biosciences Share Price Today?

    IGM Biosciences was last trading at $1.13 per share. This represents the most recent stock quote for IGM Biosciences. Yesterday, IGM Biosciences closed at $1.13 per share.

  • How To Buy IGM Biosciences Stock Online?

    In order to purchase IGM Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Do I Need to Know About Alcoa Stock?
What Do I Need to Know About Alcoa Stock?

Alcoa (AA) is a global leader in aluminum production. Based…

Is ROOT Stock the Next Big Thing?
Is ROOT Stock the Next Big Thing?

Root Holdings (NASDAQ:ROOT) is the parent company of Root Insurance,…

Is Okta a Good Stock to Buy?
Is Okta a Good Stock to Buy?

Okta (NASDAQ:OKTA) is used by some of the largest firms…

Stock Ideas

Sell
37
Is AAPL Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 31x

Sell
37
Is MSFT Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 30x

Sell
31
Is NVDA Stock a Buy?

Market Cap: $2.3T
P/E Ratio: 32x

Alerts

Sell
45
RGC alert for Apr 5

Regencell Bioscience Holdings [RGC] is up 32.59% over the past day.

Sell
25
GDXU alert for Apr 5

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 27.33% over the past day.

Buy
76
SOXS alert for Apr 5

Direxion Daily Semiconductor Bear 3X Shares [SOXS] is up 23.96% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock